Weight Loss Drug FDA Approval: Contrave Review Extended 3 Months
The weight loss drug FDA approval process for Contrave hit a significant delay when regulators extended their review by three months, pushing the expected decision date to September 11. Shares of Orexigen Therapeutics dropped more than 16% following the announcement, reflecting investor concern over the prolonged timeline for this experimental obesity treatment.
What Is Contrave and How Does It Work?
Contrave, also known as NB32, is a twice daily pill designed to reduce appetite and control cravings in patients struggling with obesity. The drug combines bupropion, the active ingredient in the antidepressant Wellbutrin, with naltrexone, an anti addiction medication. Together, these two components target the brain pathways involved in hunger and reward, making it easier for patients to stick to reduced calorie diets.
Contrave is the third in a trio of weight loss drugs recently submitted to the FDA for approval in treating obesity, a condition that affects an estimated 78 million adults in the United States.
A History of FDA Scrutiny
The weight loss drug FDA approval journey for Contrave has not been straightforward. The FDA initially refused to approve the drug in 2011, citing concerns about cardiovascular risk. Orexigen resubmitted its application in December after the drug performed well in an early analysis of a study specifically designed to rule out excessive cardiovascular risk.
Since rejecting Contrave, the FDA has approved two other obesity drugs — Qsymia from Vivus Inc. and Belviq from Arena Pharmaceuticals. Both of those drugs were also rejected in their first submission before eventually receiving approval, a pattern that reflects how rigorous the weight loss drug FDA approval process can be for this therapeutic category.
Market Challenges for Approved Obesity Drugs
Even with FDA approval, weight loss drugs have struggled commercially. Analysts originally estimated that the new obesity drugs could generate up to $1 billion in annual sales, given that more than one third of all American adults are obese. However, sales of both Qsymia and Belviq have fallen well below those projections.
The primary barrier has been insurance coverage. Vivus reported Qsymia sales of $9.1 million in its most recent quarter, while Arena and its partner Eisai reported $8.4 million in Belviq sales — numbers far below initial forecasts.
Dr. Robert Kushner of the Northwestern Comprehensive Center on Obesity explained the challenge clearly: drugs that are not covered by health plans, or are outright excluded, make it very difficult to see meaningful uptake in medication usage. Physicians often must call insurance companies directly to obtain prior authorization, creating additional friction in the prescribing process.
The Role of Medication in Obesity Treatment
Obesity treatment specialists emphasize that weight loss drugs are not standalone solutions. Dr. Kushner noted that medication serves as a window of opportunity to help patients adopt healthier dietary habits — eating more food with fewer calories rather than simply restricting intake.
Orexigen, based in La Jolla, California, has no other products on the market, making Contrave its lead candidate. If approved, the drug would be marketed in the United States by Takeda Pharmaceuticals, which would pay royalties on sales. Like Qsymia and Belviq, Contrave is designed to be used alongside dieting and exercise, not as a replacement for lifestyle changes.
Clinical Research and Obesity Studies at FOMAT
At FOMAT, we actively support clinical research in metabolic and obesity related conditions across the United States. The weight loss drug FDA approval process depends on robust clinical trial data, and investigator sites like those in the FOMAT network play a critical role in generating that evidence.
Are you interested in participating in a clinical study related to obesity or metabolic health? Visit our Active Studies page to explore current research opportunities available at FOMAT.